株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界のフォンヴィレブランド病治療市場:成長、動向、および予測(2020年~2025年)

Von Willebrand Disease Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

発行 Mordor Intelligence LLP 商品コード 921911
出版日 ページ情報 英文 111 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.54円で換算しております。
世界のフォンヴィレブランド病治療市場:成長、動向、および予測(2020年~2025年) Von Willebrand Disease Treatment Market - Growth, Trends, and Forecast (2020 - 2025)
出版日: 2020年01月01日 ページ情報: 英文 111 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

世界のフォンヴィレブランド病治療市場の成長は、治療を必要とする患者に対する医療費の増加と支援プログラムの増加により牽引されると予測されています。中でも北米は、進歩的な治療オプションの需要の急増、新技術の早期採用、患者支援プログラムの増加により市場をリードしています。ただし、病気についての認識の欠如と治療の高いコストは、予測期間中の市場成長への主な障壁の一つとなることが考えられます。

当レポートは世界のフォンヴィレブランド病治療市場について調査しており、市場機会や動向、成長および阻害要因、疾患タイプ・治療タイプ・投与経路・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 市場成長要因
    • 患者支援プログラムの増加
    • ヘルスケア支出の増加
  • 市場阻害要因
    • 認識不足
    • 高い治療費
  • ポーターのファイブフォース分析

第5章 市場セグメンテーション

  • 疾患タイプ別
    • タイプ1
    • タイプ2
    • タイプ3
    • 後天性フォンヴィレブランド病
  • 治療タイプ
    • デスモプレシン
    • 代替療法
    • 凝固安定剤
    • その他
  • 投与経路別
    • 経口
    • 注射
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • CSL Behring
    • Ferring Pharmaceuticals
    • Grifols, SA
    • Octapharma AG
    • Pfizer, Inc.
    • Sanofi SA
    • Sun Pharmaceutical Industries Ltd.
    • 武田薬品工業株式会社

第7章 市場機会および今後の動向

目次
Product Code: 67087

Market Overview

According to the World Federation of Hemophilia, Von Willebrand disease is a very common bleeding defect. People suffering from the Von Willebrand disease have a defect in the protein present in their blood, known as the Von Willebrand factor. The Von Willebrand factor helps the cells present in the blood vessel called platelets, to form a clot to control and stop bleeding.

Von Willebrand disease is a frequent inherited disorder that affects both sexes. The growing healthcare expenditure and rising number of assistance programs for patients who need treatment of von Willebrand disease are expected to drive the von Willebrand disease treatment market. However, the lack of awareness about the disease and the high cost of the treatment is among the major barrier to the growth of this market over the forecast period.

Scope of the Report

As per the scope of the report, Von Willebrand disease (VWD) is a genetic disorder that delays the process of blood clotting. It is generally caused by missing or defective von Willebrand factor (VWF), a clotting protein. VWF binds factor VIII, a key clotting protein, and platelets in blood vessel walls. Desmopressin is a common drug used for the treatment of Von Willebrand disease, which is an antidiuretic hormone that triggers the release of VWF into the plasma and may increase levels of factor VIII.

Key Market Trends

Desmopressin Segment is Expected to Register a Significant Growth in the Forecast Years

By treatment type, the market has been segmented into Desmopressin, Replacement Therapies, Clot-stabilizing Medications, and others. Desmopressin stimulates the release of VWF from cells, which also increases FVIII. This is considered to be the most preferred treatment option for patients with type 1, who account for approximately 70% to 80% of cases.

Type 1 and some subtypes of type 2 von Willebrand disease have more effective results with desmopressin as compared to the other types and thus it is expected to grow during the forecast period. In addition, growing healthcare expenditure and a large patient pool also contribute to the growth of the von Willebrand disease treatment market.

North America Leads the Von Willebrand Disease Treatment Market

North America is found leading the market owing to the upsurge in the demand for progressive treatment options, early adoption of new technologies and an increase in patient assistance programs. According to the National Hemophilia Foundation, VWD is the most common bleeding disorder, affecting up to 1% of the US population.

Europe and the Asia Pacific are followed next after North America owing to the presence of a diversified patient pool, emerging economies, and a rise in the collaboration of domestic and international companies in these regions, thus driving this market.

Competitive Landscape

The von willebrand disease treatment market is competitive and many of the global players are into the market. For instance - Bayer AG, CSL Behring, Ferring Pharmaceuticals, Grifols, Octapharma AG, Pfizer, Sanofi, Sun Pharmaceutical and Takeda are providing these products across the globe.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increase in Patient Assistance Programs
    • 4.2.2 Growing Healthcare Expenditure
  • 4.3 Market Restraints
    • 4.3.1 Lack of Awareness
    • 4.3.2 High Cost of Treatment
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Disease Type
    • 5.1.1 Type 1
    • 5.1.2 Type 2
    • 5.1.3 Type 3
    • 5.1.4 Acquired VWD
  • 5.2 Treatment Type
    • 5.2.1 Desmopressin
    • 5.2.2 Replacement Therapies
    • 5.2.3 Clot-stabilizing Medications
    • 5.2.4 Others
  • 5.3 Route of Administration
    • 5.3.1 Oral
    • 5.3.2 Injection
    • 5.3.3 Other
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 CSL Behring
    • 6.1.2 Ferring Pharmaceuticals
    • 6.1.3 Grifols, S.A.
    • 6.1.4 Octapharma AG
    • 6.1.5 Pfizer, Inc.
    • 6.1.6 Sanofi S.A.
    • 6.1.7 Sun Pharmaceutical Industries Ltd.
    • 6.1.8 Takeda Pharmaceutical Company Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS